Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as chief operating officer. In this role, Ros will be responsible for directing and operationalizing Epizyme’s launch readiness efforts for tazemetostat, and will report to Epizyme’s president and chief executive officer, Robert Bazemore.
“Matt’s proven leadership and deep commercial expertise in both oncology and rare diseases will be invaluable in developing Epizyme’s strategy for launching and commercializing tazemetostat across multiple tumor types,” said Bazemore. “Based on his experience leading strategy, commercial development, medical affairs and manufacturing, we believe Matt will have an immediate impact on the execution of Epizyme’s multi-year vision.”
“The potential opportunity with tazemetostat, combined with the depth of Epizyme’s research engine and their discovery platform, hold great promise for patients and the future of the company,” said Ros. “I look forward to working with the entire team to bring tazemetostat and other epigenetic therapies to patients in need.”
Ros comes to Epizyme from Sanofi, where he was most recently chief operating officer/global head of the Oncology Business Unit. While overseeing its $1.4 billion solid tumor and hematology franchise, he led its most recent restructuring and significantly contributed to the company’s revised business strategy. Prior to this role, Ros served in Genzyme’s Rare Disease business, leading its second largest franchise in Pompe disease as its vice president and franchise head. Ros brings more than 25 years of experience in sales, marketing, franchise strategy and operations leadership in both global pharmaceutical and early-stage biotechnology companies. Outside of his professional commitments, Ros previously served on the Board of Trustees of CancerCARE, a leading national organization dedicated to providing free, professional support services to anyone affected by cancer.